Advertisement
COR vs MCK
Which Stock Would AI Choose? Cencora Inc. (COR) vs. McKesson Corporation (MCK) Stock Comparison
Key Takeaways
- Cencora Inc. (COR) and McKesson Corporation (MCK) are two of the largest pharmaceutical distribution companies in the United States, forming part of the "Big Three" alongside Cardinal Health.
- Both stocks have demonstrated strong long-term uptrends, benefiting from consistent demand for pharmaceutical products, specialty drug growth, and expanded healthcare services.
- Recent market activity shows both companies maintaining robust revenue growth, though margin profiles and capital allocation strategies create meaningful points of differentiation.
- MCK has shown a somewhat more aggressive capital return program through share repurchases in recent periods, while COR has emphasized strategic acquisitions to expand its specialty and international footprint.
- Regulatory scrutiny around drug pricing and opioid-related litigation remains an industry-wide risk factor for both companies, though each has taken distinct approaches to managing these exposures.
- From a relative performance perspective, both stocks have outpaced the broader healthcare sector over the trailing twelve months, reflecting the defensive and resilient nature of pharmaceutical distribution.
Introduction
Comparing COR and MCK is a natural exercise for investors evaluating the pharmaceutical distribution and healthcare services sector. These two industry giants operate at the center of the U.S. drug supply chain, connecting pharmaceutical manufacturers to pharmacies, hospitals, and other healthcare providers. With combined annual revenues exceeding $500 billion, both companies command substantial market share and influence. This comparison is especially relevant for investors seeking exposure to defensive, cash-flow-generative businesses that benefit from secular tailwinds such as an aging population and rising prescription drug utilization. Understanding how COR and MCK differ in terms of growth strategy, margin structure, and risk management can help traders and long-term investors alike make more informed allocation decisions.
COR Overview and Recent Performance
COR, known as Cencora Inc. following its 2023 rebranding from AmerisourceBergen, is a global pharmaceutical sourcing and distribution powerhouse headquartered in Conshohocken, Pennsylvania. The company operates through two primary segments: U.S. Healthcare Solutions and International Healthcare Solutions. In recent weeks, COR shares have traded near their upper range, reflecting continued investor confidence in the company's execution. The stock has benefited from strong specialty pharmaceutical volume growth, particularly in oncology and gene therapy products, which carry higher margins than traditional generics. Cencora's strategic focus on expanding its manufacturer services platform, including its specialty logistics and patient support offerings, has been well-received by the market. Additionally, the company's international segment, anchored by its Alliance Healthcare and World Courier businesses, has contributed to revenue diversification. Recent quarterly results underscored resilient pharmaceutical demand trends, and the company's guidance updates have generally aligned with or modestly exceeded consensus expectations.
MCK Overview and Recent Performance
MCK, McKesson Corporation, is a diversified healthcare services company based in Irving, Texas. McKesson's operations span pharmaceutical distribution, medical-surgical supply distribution, and healthcare technology solutions through its Prescription Technology Solutions segment. The stock has demonstrated notable price resilience in recent months, supported by consistent operational execution and a disciplined capital allocation framework. McKesson has been particularly active in returning capital to shareholders; the company's share repurchase activity has accelerated in recent periods, and it has maintained a steady dividend growth trajectory. The U.S. Pharmaceutical segment continues to benefit from steady volume growth in branded and specialty drugs, while the Medical-Surgical segment has stabilized following pandemic-era volatility. McKesson's investments in oncology practice management through its Ontada platform and its focus on biopharma services have reinforced its positioning in higher-value healthcare segments. Market sentiment has remained constructive, aided by earnings reports that have regularly met or exceeded analyst forecasts.
Trending AI Robots
In today's fast-moving markets, traders and investors are increasingly turning to AI-driven tools to identify opportunities and manage risk. Tickeron's Trending AI Robots page curates a selection of the platform's most effective AI trading bots, chosen for their adaptability to current market conditions. With hundreds of AI-powered trading bots available on the platform — each trading thousands of different tickers with distinct strategies, timeframes, and risk parameters — the curated Trending section highlights those that have demonstrated the strongest alignment with prevailing market dynamics. These bots span a wide range of trading styles, from short-term momentum strategies to longer-duration trend-following approaches, and their performance statistics are available in real time for users to evaluate. For those intrigued by how artificial intelligence navigates stock comparisons like COR versus MCK, exploring the Trending AI Robots page offers a practical window into data-driven trading in action.
Head-to-Head Comparison
When evaluating COR and MCK side by side, several key contrasts emerge. On the business model front, both are anchored in pharmaceutical distribution, but McKesson's Medical-Surgical segment and technology solutions business provide a somewhat broader operational footprint. Cencora, meanwhile, has leaned more heavily into international expansion, with a significant presence in Europe through Alliance Healthcare. From a growth driver perspective, both companies are capitalizing on specialty drug proliferation, but COR's recent acquisitions in the animal health and clinical trials logistics spaces signal a distinct approach to diversification. In terms of margin profiles, both operate on thin pharmaceutical distribution margins (typically 2–4% in their core wholesale businesses), yet McKesson has demonstrated slightly stronger operating margin expansion in recent quarters. Regarding capital allocation, MCK has emphasized aggressive share buybacks, while COR has balanced repurchases with bolt-on acquisitions. On the risk side, both face opioid litigation overhang, though substantial settlement frameworks have reduced uncertainty. Sector exposure is similar, but MCK's oncology practice management and data analytics investments may offer differentiated long-term optionality.
Tickeron AI Verdict
Based on observable factors accessible to Tickeron's AI-driven analytical framework, both COR and MCK present compelling trend profiles, but the AI would likely recognize a slight edge for McKesson in the current environment. MCK's combination of consistent price trend stability, robust free cash flow generation supporting aggressive share repurchases, and a broader operational moat through its Medical-Surgical and technology segments suggests a marginally higher probability of sustained relative outperformance. That said, Cencora's international diversification and specialty logistics capabilities provide meaningful counterbalancing strengths. The AI verdict is probabilistic rather than absolute: both stocks exhibit characteristics that quantitative models favor, including strong relative strength versus their sector and well-defined support levels. Ultimately, the AI's preference reflects McKesson's slightly more favorable alignment of momentum, capital return policy, and business diversification in the current market landscape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COR is a StrongBuy and MCK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COR’s FA Score shows that 2 FA rating(s) are green whileMCK’s FA Score has 2 green FA rating(s).
- COR’s FA Score: 2 green, 3 red.
- MCK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COR’s TA Score shows that 5 TA indicator(s) are bullish while MCK’s TA Score has 6 bullish TA indicator(s).
- COR’s TA Score: 5 bullish, 5 bearish.
- MCK’s TA Score: 6 bullish, 4 bearish.
Price Growth
COR (@Medical Distributors) experienced а +0.65% price change this week, while MCK (@Medical Distributors) price change was -0.06% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was -2.45%. For the same industry, the average monthly price growth was +1.07%, and the average quarterly price growth was -9.41%.
Reported Earning Dates
COR is expected to report earnings on Aug 05, 2026.
MCK is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Medical Distributors (-2.45% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
| COR | MCK | COR / MCK | |
| Capitalization | 60.3B | 98.5B | 61% |
| EBITDA | 5.03B | 7.18B | 70% |
| Gain YTD | -7.880 | 2.711 | -291% |
| P/E Ratio | 23.75 | 21.91 | 108% |
| Revenue | 329B | 403B | 82% |
| Total Cash | 2.18B | 3.98B | 55% |
| Total Debt | 12.4B | 8.61B | 144% |
COR | MCK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 80 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 30 | 17 | |
SMR RATING 1..100 | 11 | 100 | |
PRICE GROWTH RATING 1..100 | 51 | 47 | |
P/E GROWTH RATING 1..100 | 81 | 72 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MCK's Valuation (13) in the Medical Distributors industry is somewhat better than the same rating for COR (68) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew somewhat faster than COR’s over the last 12 months.
MCK's Profit vs Risk Rating (17) in the Medical Distributors industry is in the same range as COR (30) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew similarly to COR’s over the last 12 months.
COR's SMR Rating (11) in the Real Estate Investment Trusts industry is significantly better than the same rating for MCK (100) in the Medical Distributors industry. This means that COR’s stock grew significantly faster than MCK’s over the last 12 months.
MCK's Price Growth Rating (47) in the Medical Distributors industry is in the same range as COR (51) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew similarly to COR’s over the last 12 months.
MCK's P/E Growth Rating (72) in the Medical Distributors industry is in the same range as COR (81) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew similarly to COR’s over the last 12 months.
| COR | MCK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 47% | 1 day ago 39% |
| Stochastic ODDS (%) | 1 day ago 51% | 1 day ago 38% |
| Momentum ODDS (%) | 1 day ago 60% | 1 day ago 63% |
| MACD ODDS (%) | 1 day ago 44% | 1 day ago 78% |
| TrendWeek ODDS (%) | 1 day ago 62% | 1 day ago 39% |
| TrendMonth ODDS (%) | 1 day ago 62% | 1 day ago 68% |
| Advances ODDS (%) | 1 day ago 61% | 1 day ago 65% |
| Declines ODDS (%) | 4 days ago 43% | 4 days ago 43% |
| BollingerBands ODDS (%) | 1 day ago 47% | 1 day ago 45% |
| Aroon ODDS (%) | 1 day ago 61% | 1 day ago 73% |
Advertisement
COR and
Correlation & Price change
A.I.dvisor indicates that over the last year, COR has been closely correlated with MCK. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if COR jumps, then MCK could also see price increases.
| Ticker / NAME | Correlation To COR | 1D Price Change % | ||
|---|---|---|---|---|
| COR | 100% | +1.58% | ||
| MCK - COR | 70% Closely correlated | +1.99% | ||
| CAH - COR | 57% Loosely correlated | +0.91% | ||
| FOCL - COR | 7% Poorly correlated | -0.99% | ||
| YI - COR | 6% Poorly correlated | -4.85% | ||
| HSIC - COR | 5% Poorly correlated | +1.11% | ||
More | ||||
MCK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MCK has been closely correlated with COR. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if MCK jumps, then COR could also see price increases.
| Ticker / NAME | Correlation To MCK | 1D Price Change % | ||
|---|---|---|---|---|
| MCK | 100% | +1.99% | ||
| COR - MCK | 71% Closely correlated | +1.58% | ||
| CAH - MCK | 68% Closely correlated | +0.91% | ||
| HKPD - MCK | 10% Poorly correlated | +10.33% | ||
| COSM - MCK | 9% Poorly correlated | +0.05% | ||
| YI - MCK | 6% Poorly correlated | -4.85% | ||
More | ||||